2013-09-02 14:28:11 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to CytRx Corporation (CYTR) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering CytRx Corporation (CYTR). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential CytRx Corporation investor.
Report Summary: CytRx Corporation is a low quality company with a neutral outlook. CytRx Corporation has weak business growth and is run by inefficient management. The trend in CytRx Corporation fair value exchange rate against its closest rated-competitor, StemCells Inc, has been appreciating over the past 2 weeks. When compared to its closest competitor, CytRx Corporation shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three components - business, management and price, performing
an in-depth analysis of CytRx Corporation for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.